The funding will be used to expand Alibaba’s data centres, strengthen its AI infrastructure, and integrate AI across its core businesses, including e-commerce, cloud computing, and consumer ...

The tech and cybersecurity solutions provider attributes growth mainly to acquisitions, resulting in narrowed losses.

Seven key charts worth watching are: Trump’s tariffs; long term inflation expectations; inflation; business conditions PMIs; profit growth; the gap between earnings yields and bond yields; and the $US ...

Starbucks has announced plans to lay off 1,100 corporate employees and cut nearly a third of its US menu as part of a major effort to turn around struggling sales in its home market. The job cuts, the ...

Viva Energy (ASX: VEA) has reported a 5% increase in EBITDA (RC) to $748.6 million for the 2024 financial year, driven by strong fuel sales and strategic acquisitions. The company’s fuel sales rose 4% ...

Company expects full-year EBITDA to exceed $10 million, showcasing strong performance and continued AI investment.

Brookside Energy has commenced drilling its ninth well, the Bruins 2-11-1S-3W WXH1 well, in the Anadarko Basin, Oklahoma.

XPON Technologies Group (ASX: XPN) has released its Appendix 4D and half-yearly report for H1 FY25, showcasing impressive financial results and strategic progress. The company’s continuing business, ...

Ambertech Limited (ASX:AMO) reports a decline in revenue and profit for the first half of FY25, but anticipates improvement in the second half.

The Sangomar oilfield ramped up to full capacity within nine weeks of its June 2024 startup, delivering 12.9 million barrels of oil equivalent in sales and $950 million in revenue. Woodside also made ...

Despite the decline in sales, gross margin fell only 2.2 percentage points, as Alexium continued its strategic shift towards higher-margin foam mattress applications. The company has also expanded its ...

Race Oncology Limited (ASX: RAC) has released its half-year financial report, demonstrating a significant turnaround in profitability and promising advancements in clinical trials.